新型半合成棘白菌素LY-303366对氟康唑敏感及耐药念珠菌属的体外杀菌曲线
In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species.
作者信息
Karlowsky J A, Harding G A, Zelenitsky S A, Hoban D J, Kabani A, Balko T V, Turik M, Zhanel G G
机构信息
Faculty of Pharmacy, University of Manitoba, Winnipeg, Canada.
出版信息
Antimicrob Agents Chemother. 1997 Nov;41(11):2576-8. doi: 10.1128/AAC.41.11.2576.
Abstract
In vitro killing by a new semisynthetic echinocandin, LY-303366, was characterized using clinical isolates of fluconazole-sensitive (Y58) and -resistant (Y180) Candida albicans as well as Candida glabrata (Y7) and Candida krusei (Y171). The 24-h kill curves for Y58 and Y180 demonstrated dose-independent killing of between 1 and 2 log10 with LY-303366 at concentrations of 0.1, 1, 10, 50, 100, and 1,000 times the MIC. Regrowth did not occur at 24 h with either C. albicans isolate at the aforementioned LY-303366 concentrations. At their MICs, LY-303366 and amphotericin B produced similar killing kinetics in cultures of Y58, Y180, Y7, and Y171, while all cultures exposed to fluconazole at its MIC demonstrated stasis or growth over 24 h.
摘要
使用氟康唑敏感（Y58）和耐药（Y180）的白色念珠菌临床分离株以及光滑念珠菌（Y7）和克柔念珠菌（Y171），对一种新型半合成棘白菌素LY - 303366的体外杀菌特性进行了研究。Y58和Y180的24小时杀菌曲线表明，在LY - 303366浓度为MIC的0.1、1、10、50、100和1000倍时，杀菌效果为1至2个对数级，且与剂量无关。在上述LY - 303366浓度下，两种白色念珠菌分离株在24小时均未出现再生长。在Y58、Y180、Y7和Y171的培养物中，LY - 303366和两性霉素B在其MIC时产生相似的杀菌动力学，而所有暴露于氟康唑MIC的培养物在24小时内均表现为生长停滞或生长。
相似文献
1
In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species.
Antimicrob Agents Chemother. 1997 Nov;41(11):2576-8. doi: 10.1128/AAC.41.11.2576.
2
Candida and candidaemia. Susceptibility and epidemiology.
Dan Med J. 2013 Nov;60(11):B4698.
3
Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
J Antimicrob Chemother. 2000 Sep;46(3):475-7. doi: 10.1093/jac/46.3.475.
4
In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.
Clin Microbiol Infect. 2001 Jan;7(1):11-6. doi: 10.1046/j.1469-0691.2001.00158.x.
5
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.
Diagn Microbiol Infect Dis. 2002 May;43(1):13-7. doi: 10.1016/s0732-8893(02)00361-9.
6
In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.
Antimicrob Agents Chemother. 1997 May;41(5):1156-7. doi: 10.1128/AAC.41.5.1156.
7
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
J Clin Microbiol. 2005 Nov;43(11):5425-7. doi: 10.1128/JCM.43.11.5425-5427.2005.
8
In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.
Antimicrob Agents Chemother. 1997 Apr;41(4):863-5. doi: 10.1128/AAC.41.4.863.
9
Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.
J Antimicrob Chemother. 2003 Jan;51(1):163-6. doi: 10.1093/jac/dkg018.
10
Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
J Clin Microbiol. 2006 Feb;44(2):324-6. doi: 10.1128/JCM.44.2.324-326.2006.
引用本文的文献
1
Antifungal Peptides as Therapeutic Agents.
Front Cell Infect Microbiol. 2020 Mar 17;10:105. doi: 10.3389/fcimb.2020.00105. eCollection 2020.
2
In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.
J Clin Microbiol. 2010 Jul;48(7):2613-4. doi: 10.1128/JCM.00806-10. Epub 2010 May 26.
3
In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies.
Antimicrob Agents Chemother. 2010 May;54(5):2194-7. doi: 10.1128/AAC.01538-09. Epub 2010 Feb 9.
4
In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.
Antimicrob Agents Chemother. 2009 Jul;53(7):3108-11. doi: 10.1128/AAC.00160-09. Epub 2009 Apr 20.
5
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2008 May;52(5):1635-41. doi: 10.1128/AAC.01071-07. Epub 2008 Feb 19.
6
Anidulafungin.
Drugs. 2004;64(19):2249-58; discussion 2259-60. doi: 10.2165/00003495-200464190-00011.
7
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
Antimicrob Agents Chemother. 2001 Oct;45(10):2845-55. doi: 10.1128/AAC.45.10.2845-2855.2001.
8
Influence of human serum on antifungal pharmacodynamics with Candida albicans.
Antimicrob Agents Chemother. 2001 Jul;45(7):2018-22. doi: 10.1128/AAC.45.7.2018-2022.2001.
9
Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
Antimicrob Agents Chemother. 2001 Feb;45(2):471-9. doi: 10.1128/AAC.45.2.471-479.2001.
本文引用的文献
1
In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.
Antimicrob Agents Chemother. 1997 Apr;41(4):863-5. doi: 10.1128/AAC.41.4.863.
2
Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.
Diagn Microbiol Infect Dis. 1996 Nov-Dec;26(3-4):125-31. doi: 10.1016/s0732-8893(96)00202-7.
3
Mechanisms and clinical impact of antifungal drug resistance.
J Med Vet Mycol. 1994;32 Suppl 1:189-202. doi: 10.1080/02681219480000821.
4
Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.
Am J Med. 1991 Sep 16;91(3B):86S-89S. doi: 10.1016/0002-9343(91)90349-3.
5
Impact of the changing epidemiology of fungal infections in the 1990s.
Eur J Clin Microbiol Infect Dis. 1992 Apr;11(4):287-91. doi: 10.1007/BF01962067.
Zotero 插件